Oncode Institute
Overview
Oncode Institute is a Dutch cancer research and innovation organization that provides pre-seed and seed investments to oncology-focused spin-off companies through its Oncode Oncology Bridge Fund.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Flindr Therapeutics | Apr 2024 | Series A | Co-investor |
| Laigo Bio | Mar 2026 | Seed | Co-investor |
| Single Cell Discoveries | Sep 2018 | Seed | Lead |
Key People
René Kuijten
Initiator & Founder, Vice-chairman Supervisory Board
Carolien Hovenier
Patient Partner
Gerrit Oostenveld
Patient Partner
Anne Rios
Principal Investigator
Jacco van Rheenen
Principal Investigator
Jop Kind
Principal Investigator
Lodewyk Wessels
Oncode Principal Investigator
Louis Vermeulen
Principal Investigator
Madelon Maurice
Principal Investigator
Mario van der Stelt
Principal Investigator
Miao-Ping Chien
Principal Investigator
Rebekka K. Schneider
Principal Investigator
Ruben van Boxtel
Principal Investigator At The Princess Máxima Center And Oncode Institute
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Oncode Institute based?
Oncode Institute is headquartered in Utrecht, Netherlands.
When was Oncode Institute founded?
Oncode Institute was founded in 2017.
How many portfolio companies does Oncode Institute have?
Oncode Institute has 3 portfolio companies in Caplight's dataset.
What are some companies in Oncode Institute's portfolio?
Portfolio companies visible on Caplight include Flindr Therapeutics, Laigo Bio, Single Cell Discoveries.
What was Oncode Institute's most recent investment shown here?
Oncode Institute's most recent investment in this portfolio sample was in Laigo Bio in 2026.
What sectors does Oncode Institute focus on?
Oncode Institute focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Oncode Institute focus on?
Oncode Institute typically invests at the Early stage.